Back to Search
Start Over
Hepatocellular carcinoma (HCC) Tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) Tumor microenvironment
- Publication Year :
- 2023
- Publisher :
- Research Square Platform LLC, 2023.
-
Abstract
- Background and purpose: HCC is inflammation-associated cancer and develops on chronic inflamed liver while CRLM develop on permissive healthy liver microenvironment. To evaluate the immune aspects of these two different environments, peripheral blood-(PB), peritumoral-(PT) and tumoral tissues-(TT) from HCC and CRLM patients were evaluated. Methods: 40 HCC and 34 CRLM were enrolled and freshly TT, PT and PB were collected at the surgery. PB-, PT- and TT-derived CD4+CD25+ Tregs and PB-derived CD4+CD25− Teffector cells (Teffs) were isolated and characterized for phenotype and function. Tregs function was evaluated in the presence of Peptide-R29, AMD3100 or anti-PD-1. RNA was extracted from PB/PT/TT-tissues and tested for FOXP3, CXCL12, CXCR4, CCL5, IL-15, CXCL5, Arg-1, N-cad, Vim, CXCL8, TGFb and VEGF-A expression. Results: In HCC/CRLM-PB higher number of functional Tregs, CD4+CD25hiFOXP3+ were detected, although PB-HCC Tregs exert a more suppressive function as compared to CRLM-Tregs. In HCC/CRLM-TT Tregs were highly represented with Activated/ENTPD-1+Tregs prevalent in HCC. As compared to CRLM, HCC overexpressed CXCR4 and N-cadherin/Vimentin in a contest rich of arginase and CCL5. Monocytic-MDSCs were highly represented in HCC/CRLM while high Polymorphonuclear-MDSCs were detected only in HCC. Interestingly, CXCR4-PB-Tregs inhibition, through the inhibitor-R29, impaired Tregs function in HCC/CRLM. Conclusion: in HCC and CRLM, peripheral blood, peritumoral and tumoral tissues-Tregs are highly represented and functional. Nevertheless, HCC display a more immunosuppressive TME due to Tregs, MDSCs, intrinsic tumor features (CXCR4, CCL5, arginase) and the contest in which it develops. As CXCR4 is overexpressed in HCC/CRLM tumor/TME cells, CXCR4 inhibitors may be considered for double hits therapy in liver cancer patients.
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi...........fd05ccff1948ca3ce0bbfcfb5b2899af
- Full Text :
- https://doi.org/10.21203/rs.3.rs-2419131/v1